{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:54Z","timestamp":1760239854402,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.hoc.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T02:15:31Z","timestamp":1621995331000},"page":"715-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genomics of Resistance to Targeted Therapies"],"prefix":"10.1016","volume":"35","author":[{"given":"Shanmugapriya","family":"Thangavadivel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.hoc.2021.03.004_bib1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","article-title":"Acquired initiating mutations in early hematopoietic cells of CLL patients","volume":"4","author":"Damm","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.hoc.2021.03.004_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ccr.2011.06.029","article-title":"Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia","volume":"20","author":"Kikushige","year":"2011","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2021.03.004_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2021.03.004_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-13-0349","article-title":"Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia","volume":"4","author":"Oakes","year":"2014","journal-title":"Cancer Discov"},{"issue":"26","key":"10.1016\/j.hoc.2021.03.004_bib5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7354","key":"10.1016\/j.hoc.2021.03.004_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"7574","key":"10.1016\/j.hoc.2021.03.004_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2021.03.004_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hoc.2021.03.004_bib10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.004_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2021.03.004_bib12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.004_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2021.03.004_bib15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2021.03.004_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2021.03.004_bib17","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10238","key":"10.1016\/j.hoc.2021.03.004_bib18","first-page":"1694","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial (vol 395, pg 1278, 2020)","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.hoc.2021.03.004_bib19","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"29","key":"10.1016\/j.hoc.2021.03.004_bib20","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2021.03.004_bib21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2021.03.004_bib22","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2021.03.004_bib23","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2021.03.004_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2021.03.004_bib25","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.03.004_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/gm451","article-title":"Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics","volume":"5","author":"Landau","year":"2013","journal-title":"Genome Med"},{"issue":"26","key":"10.1016\/j.hoc.2021.03.004_bib27","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2021.03.004_bib28","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"7247","key":"10.1016\/j.hoc.2021.03.004_bib29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappa B in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2021.03.004_bib30","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.hoc.2021.03.004_bib31","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-MEDIATED RESISTANCE TO IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUkemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.03.004_bib32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.03.004_bib33","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1538-7445.AM2017-3150","article-title":"PLCG2 C2-domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing treatment with the BTK inhibitor ibrutinib","volume":"77","author":"Jones","year":"2017","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.hoc.2021.03.004_bib34","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2021.03.004_bib35","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.004_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","author":"Gang","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.004_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"42","key":"10.1016\/j.hoc.2021.03.004_bib38","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.004_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.004_bib40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.004_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"SUPPL 1","key":"10.1016\/j.hoc.2021.03.004_bib42","first-page":"5","article-title":"Activation of phospholipase C-Y-2 mutants mediating ibruntinib resistance in human chronic lymphocytic leukemia cells by non-catalytic functions of Bruton's tyrosine kinase. Naunyn-schmiedebergs","volume":"393","author":"Wist","year":"2020","journal-title":"Arch Pharmacol"},{"issue":"42","key":"10.1016\/j.hoc.2021.03.004_bib43","doi-asserted-by":"crossref","first-page":"22136","DOI":"10.1074\/jbc.M116.746842","article-title":"The Phospholipase C gamma(2) Mutants R665W and L845F identified in ibrutinib-resistant chronic lymphocytic leukemia patients are hypersensitive to the rho GTPase Rac2 Protein","volume":"291","author":"Walliser","year":"2016","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"10.1016\/j.hoc.2021.03.004_bib44","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2021.03.004_bib45","doi-asserted-by":"crossref","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.004_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.hoc.2021.03.004_bib47","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/leu.2017.100","article-title":"Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1","volume":"31","author":"Cosson","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.004_bib48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.03.004_bib49","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fonc.2020.00894","article-title":"Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents","volume":"10","author":"Sedlarikova","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.03.004_bib50","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2021.03.004_bib51","first-page":"860","article-title":"Targeting neoplastic B cells and harnessing microenvironment: the \"double face\" of ibrutinib and idelalisib","author":"Maffei","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.004_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.004_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A\u00a0phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.004_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2021.03.004_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to Acalabrutinib in CLL is mediated primarily by BTK Mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.004_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-020-0715-5","article-title":"Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape","volume":"21","author":"Iovino","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.hoc.2021.03.004_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp-a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK Inhibitor Zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2021.03.004_bib58","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","article-title":"Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO\/GS-4059","volume":"129","author":"Walter","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.004_bib59","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","article-title":"Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia","volume":"26","author":"Danilov","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.hoc.2021.03.004_bib60","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3 '-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"134","key":"10.1016\/j.hoc.2021.03.004_bib61","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K Isoforms p110 alpha and p110 delta are essential for pre-B cell receptor signaling and B cell development","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signaling"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.004_bib62","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ajh.25243","article-title":"Duvelisib, an oral dual PI3K-, inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Article","volume":"93","author":"O'Brien","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2021.03.004_bib63","first-page":"103","article-title":"Duvelisib (IPI-145), an oral dual inhibitor of PI3K-delta,gamma, is clinically active in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"56","author":"O'Brien","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2021.03.004_bib64","first-page":"130","article-title":"KI Intolerance study: a phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy","author":"Mato","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.004_bib65","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases gamma and delta in malignant B cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2021.03.004_bib66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110 delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2021.03.004_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2770.2770","article-title":"Whole-exome sequencing revealed no recurrent mutations within the PI3K Pathway in relapsed chronic lymphocytic leukemia patients progressing under idelalisib treatment","volume":"128","author":"Ghia","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2021.03.004_bib68","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-delta inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.03.004_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115304","article-title":"Activating MAPK pathway mutations mediate primary resistance to PI3K inhibitors in chronic lymphocytic leukemia (CLL)","volume":"132","author":"Murali","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.03.004_bib70","first-page":"1","article-title":"BCL-2 Protein Family: Essential Regulators of Cell Death","volume":"687","author":"Hetz","year":"2010","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.004_bib71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2021.03.004_bib72","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.004_bib73","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2021.03.004_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","article-title":"A\u00a0new wave in hematooncology","volume":"61","author":"Mihalyova","year":"2018","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hoc.2021.03.004_bib75","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.hoc.2021.03.004_bib76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val Mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.004_bib77","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.hoc.2021.03.004_bib78","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:16:02Z","timestamp":1760184962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0889858821000368"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.03.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomics of Resistance to Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}